Stockscreener 앱 받기
0.68
10.51%
-0.0799
시간 외 거래:
.68
전일 마감가:
$0.7599
열려 있는:
$0.6699
하루 거래량:
168.50K
Relative Volume:
0.49
시가총액:
$N/A
수익:
$237.26M
순이익/손실:
$16.33M
주가수익비율:
11.47
EPS:
0.0593
순현금흐름:
$7.57M
1주 성능:
-10.51%
1개월 성능:
-2.72%
6개월 성능:
+70.77%
1년 성능:
-35.85%
1일 변동 폭
$0.6503
$0.69
1주일 범위
$0.6503
$0.69
52주 변동 폭
$0.33
$0.80
Vaxart Inc Stock (VXRT) Company Profile
Compare VXRT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.68 | 0 | 237.26M | 16.33M | 7.57M | 0.0593 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-15 | 개시 | Oppenheimer | Outperform |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-29 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | 개시 | Jefferies | Buy |
| 2021-06-11 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
모두보기
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart (VXRT) Institutional Ownership 2026 $VXRT - MarketBeat
MSN Money - MSN
Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release - MSN
Vaxart (VXRT) Reports Progress in Clinical Programs and Financia - GuruFocus
VXRT: Revenue surged and net income turned positive as clinical milestones and funding flexibility advanced - TradingView
Earnings call transcript: Vaxart’s mixed Q1 2026 results, EPS beats forecast By Investing.com - Investing.com South Africa
VXRT: Revenue doubled year-over-year, with clinical milestones and cash runway into Q2 2027 - TradingView
[S-1] Vaxart, Inc. Files IPO Registration Statement - Stock Titan
Earnings call transcript: Vaxart’s mixed Q1 2026 results, EPS beats forecast - Investing.com
Vaxart Q1 2026 Earnings Call Transcript - MarketBeat
Vaxart : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Vaxart targets Q2 data from 400-person oral COVID vaccine study - Stock Titan
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vaxart (OTCQX: VXRT) swings to Q1 2026 profit on BARDA and collaboration revenue - Stock Titan
Vaxart (OTCQX: VXRT) swings to Q1 2026 profit as COVID trial advances - Stock Titan
Vaxart (VXRT) files ATM supplement to raise up to $49.8M via Sales Agents - Stock Titan
Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts - MSN
Vaxart (VXRT) director James B. Breitmeyer files initial Form 3 with no trades - Stock Titan
Vaxart (NASDAQ: VXRT) awards 78,800 RSUs and 157,400 options to director - Stock Titan
Earnings Preview: Vaxart to Report Financial Results Post-market on May 07 - Moomoo
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET - The Manila Times
Vaxart to report Q1 2026 results May 7 and host stockholder chat May 8 - Pluang
[EFFECT] Vaxart, Inc. SEC Filing - Stock Titan
Q3 2025 Vaxart Inc Earnings Call Transcript - GuruFocus
VXRT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vaxart (OTCQX: VXRT) outlines 2025 governance, pay and ownership - Stock Titan
Akin, an Elite Global Law Firm - Akin
Vaxart Investors Come Up Empty in Trial Against Insider Fund (3) - Bloomberg Law News
BREAKING: Jury Clears Armistice Capital, Execs Of Securities Fraud - Law360
Book value per share of Vaxart, Inc. – MUN:NB11 - TradingView
Jury Clears Armistice Capital, Execs Of Securities Fraud - Law360
Did Hedge Fund 'Greed' Hurt Vaxart Investors? Jury To Decide - Law360
Vaxart announces $25M share purchase agreement - MSN
The 3 penny stocks you swore you'd never buy (but you'll check anyway) - MSN
Vaxart (OTCMKTS:VXRT) Stock Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Vaxart, Inc. Files Form 8-K for Common Stock (VXRT) on April 23, 2026 – Company Details and SEC Compliance - Minichart
Vaxart adds James Breitmeyer to board of directors By Investing.com - Investing.com Australia
Vaxart Adds Veteran Biotech Leader to Board - TipRanks
Vaxart adds James Breitmeyer to board of directors - Investing.com
Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors to Enhance Clinical Development and Regulatory Expertise - Quiver Quantitative
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors - The Manila Times
Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors - marketscreener.com
Press Release: Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors - Moomoo
Vaxart, Inc. Files Form 8-K with SEC – Company Information and Details for April 20, 2026 - Minichart
Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky' - Law360
Vaxart amends lease to add Utah Avenue space, ends Harbor Way lease in May - Investing.com Canada
Vaxart amends lease to add Utah Avenue space, ends Harbor Way lease in May By Investing.com - Investing.com South Africa
Vaxart Inc (VXRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
자본화:
|
볼륨(24시간):